Media coverage
1
Media coverage
Title Findings support 120 mg daily as preferred belzutifan dose for advanced clear cell RCC Media name/outlet Healio Country/Territory United States Date 11/11/23 URL https://www.healio.com/news/hematology-oncology/20231111/findings-support-120-mg-daily-as-preferred-belzutifan-dose-for-advanced-clear-cell-rcc Persons Pooja Ghatalia